Five Prime Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
The model of this well-financed two-year-old start-up harks back to the mid-to-late 1990s when technology promised to provide industrial-age solutions to the handcraft of drug R&D. Its investor list likewise recalls earlier years: one of its key venture funds, Kleiner Perkins, once at the forefront of biotech investing has largely remained on the sidelines since the mid-1990s. Even its vocabulary echoes older ambitions--FivePrime aims to mine the pharmanome, just as companies in the late 1990s aimed to mine the proteome, peptidome, metabolome, cytome, glycome and cellome.
You may also be interested in...
The Key to Turning Technology into Products? Management.
The fundamental business model for platform technology companies hasn't changed: Build the platform, and apply the resulting discovery capability to internal product development while leveraging its value to raise cash or barter for resources. But investors today prefer companies that can articulate a short route to proof-of-concept data,. And unlike 6-10 years ago, more start-ups are now being formed around clinically savvy drug development teams that are better able to select alternative paths to near-term opportunities--be it in-licensing or even M&A--that allows companies greater flexibility.
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.